$-0.16 EPS Expected for Sierra Oncology, Inc. (SRRA)

July 14, 2018 - By Andrea Pope

Analysts expect Sierra Oncology, Inc. (NASDAQ:SRRA) to report $-0.16 EPS on August, 9.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. After having $-0.19 EPS previously, Sierra Oncology, Inc.’s analysts see -15.79 % EPS growth. The stock decreased 1.39% or $0.04 during the last trading session, reaching $2.84. About 290,540 shares traded. Sierra Oncology, Inc. (NASDAQ:SRRA) has risen 100.00% since July 14, 2017 and is uptrending. It has outperformed by 87.43% the S&P500.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response therapeutics for the treatment of patients with cancer in the United States and internationally. The company has market cap of $211.05 million. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It currently has negative earnings. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage.

More important recent Sierra Oncology, Inc. (NASDAQ:SRRA) news were published by: Benzinga.com which released: “38 Biggest Movers From Yesterday” on June 14, 2018, also Benzinga.com published article titled: “25 Stocks Moving In Friday’s Pre-Market Session”, Investingnews.com published: “Biotech Update: Q2 2018 in Review” on July 11, 2018. More interesting news about Sierra Oncology, Inc. (NASDAQ:SRRA) was released by: Benzinga.com and their article: “30 Stocks Moving In Friday’s Mid-Day Session” with publication date: June 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.